{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:47:42Z","timestamp":1779342462796,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006477","name":"National Taiwan University","doi-asserted-by":"publisher","award":["109F004T"],"award-info":[{"award-number":["109F004T"]}],"id":[{"id":"10.13039\/501100006477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jfma.2022.08.017","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T07:29:47Z","timestamp":1661930987000},"page":"2438-2445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021"],"prefix":"10.1016","volume":"121","author":[{"given":"Kuan-Yin","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-6250","authenticated-orcid":false,"given":"Ming-Ju","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Man","family":"Ieong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-0370","authenticated-orcid":false,"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2022.08.017_bib2","first-page":"1","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review","author":"Mohammed","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jfma.2022.08.017_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know so far","volume":"72","author":"Fung","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2022.08.017_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jfma.2020.11.021","article-title":"Vaccine efficacy against COVID-19: a foresight on the host-associated factors","volume":"120","author":"Priyanka","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.08.017_bib5","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2022.08.017_bib6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMe2202547","article-title":"Addressing vaccine inequity - covid-19 vaccines as a global public good","volume":"386","author":"Hunter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.08.017_bib7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.08.017_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2022.08.017_bib10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0140-6736(22)00089-7","article-title":"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden","volume":"399","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2022.08.017_bib13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jfma.2022.02.020","article-title":"Immune response and safety of heterologous ChAdOx1-nCoV-19\/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination","volume":"121","author":"Sheng","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.08.017_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jfma.2022.08.017_bib15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of Viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.08.017_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40001-022-00648-5","article-title":"Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis","volume":"27","author":"Mehrabi Nejad","year":"2022","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jfma.2022.08.017_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.08.017_bib18","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.08.017_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2021-221558","article-title":"Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2022.08.017_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00014-21","article-title":"Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection","volume":"95","author":"Chen","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.jfma.2022.08.017_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2022.08.017_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4110\/in.2010.10.3.92","article-title":"Cyclooxygenase inhibitors, aspirin and ibuprofen, inhibit MHC-restricted antigen presentation in dendritic cells","volume":"10","author":"Kim","year":"2010","journal-title":"Immune Netw"},{"key":"10.1016\/j.jfma.2022.08.017_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/ciab516","article-title":"The potential declining efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) on inoculators with nonsteroidal anti-inflammatory drug (NSAID) intake","volume":"74","author":"Yeh","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2022.08.017_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-022-00453-5","article-title":"Use of analgesics\/antipyretics in the management of symptoms associated with COVID-19 vaccination","volume":"7","author":"Ooi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jfma.2022.08.017_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jfma.2021.08.022","article-title":"Epidemic trend of COVID-19 in Taiwan, may to June 2021","volume":"121","author":"Lee","year":"2022","journal-title":"J Formos Med Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622003278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622003278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:49:36Z","timestamp":1760539776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622003278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0929664622003278"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.08.017","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}